---
title: "SURMOUNT-2: Tirzepatide Phase 3 Results | Primara Labs"
url: https://www.primaralabs.com/research/trials/surmount-2
source: Primara Labs, markdown mirror of the HTML page
---

# SURMOUNT-2

In SURMOUNT-2, a phase 3 trial of tirzepatide in adults (18 or older) with BMI of 27 kg/m2 or higher and type 2 diabetes with HbA1c 7-10% (53-86 mmol/mol), in seven countries (n=938), mean body weight fell 12.8% on 10 mg and 14.7% on 15 mg over 72 weeks, against 3.2% on placebo (treatment-regimen estimand; Garvey WT et al. Lancet 2023 (SURMOUNT-2)).

Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked.

Updated 24 September 2026

Tirzepatide Explained: SURMOUNT, SURPASS and Philippines Status1:58·[Transcript and chapters](https://www.primaralabs.com/videos/tirzepatide)

## Results

Mean percent change in body weight by arm, as each source reports it. Navy bars are the trial arms, grey bars the comparator. Bars from different trials are not a head-to-head comparison: populations, durations and estimands differ.

## Side effects reported

SURMOUNT-2: The abstract reports that few adverse events led to discontinuation (under 5%) without per-arm figures.

Design

## Trial design and sources

Compound

Tirzepatide

Phase

3

Population

Adults (18 or older) with BMI of 27 kg/m2 or higher and type 2 diabetes with HbA1c 7-10% (53-86 mmol/mol), in seven countries

Participants randomised

938

Duration

72 weeks

Primary endpoint

Coprimary: percent change in bodyweight from baseline and bodyweight reduction of 5% or higher (week 72)

Estimand

treatment-regimen

Read out

26 June 2023

The abstract reports that few adverse events led to discontinuation (under 5%) without per-arm figures.

-   Garvey WT et al. Lancet 2023 (SURMOUNT-2) [open](https://doi.org/10.1016/s0140-6736(23)01200-x) · checked 23 September 2026
-   ClinicalTrials.gov NCT04657003 [open](https://clinicaltrials.gov/study/NCT04657003) · checked 23 September 2026
-   Registry: NCT04657003

Questions

## SURMOUNT-2, answered

### What did SURMOUNT-2 find?

In SURMOUNT-2, a phase 3 trial of tirzepatide in adults (18 or older) with BMI of 27 kg/m2 or higher and type 2 diabetes with HbA1c 7-10% (53-86 mmol/mol), in seven countries (n=938), mean body weight fell 12.8% on 10 mg and 14.7% on 15 mg over 72 weeks, against 3.2% on placebo (treatment-regimen estimand; Garvey WT et al. Lancet 2023 (SURMOUNT-2)).

### What side effects were reported in SURMOUNT-2?

SURMOUNT-2: The abstract reports that few adverse events led to discontinuation (under 5%) without per-arm figures.

Related

## More on tirzepatide

-   [TRIUMPH-5](https://www.primaralabs.com/research/trials/triumph-5)
-   [SURMOUNT-1](https://www.primaralabs.com/research/trials/surmount-1)
-   [SURMOUNT-3](https://www.primaralabs.com/research/trials/surmount-3)
-   [SURMOUNT-4](https://www.primaralabs.com/research/trials/surmount-4)
-   [SURMOUNT-5](https://www.primaralabs.com/research/trials/surmount-5)
-   [Evidence Map: Tirzepatide](https://www.primaralabs.com/research/evidence#tirzepatide)
-   [Tirzepatide 15mg](https://www.primaralabs.com/marketplace/tirzepatide-15mg)

## More videos

Semaglutide vs Tirzepatide: Head-to-Head Trial (Philippines)1:53·[Transcript and chapters](https://www.primaralabs.com/videos/semaglutide-vs-tirzepatide)